US2006257965A1PendingUtilityA1

Extracellular matrix signalling molecules

Individually held — no corporate assignee on recordPriority: Mar 15, 1996Filed: Jun 19, 2006Published: Nov 16, 2006
Est. expiryMar 15, 2016(expired)· nominal 20-yr term from priority
Inventors:Lester Lau
A61P 9/00A61P 43/00A61P 35/00A61P 19/00A61P 17/00C07K 2317/76C07K 16/18C12N 2799/026A61K 38/00C07K 14/475A01K 2217/05C07K 2317/73A61P 17/02A61P 11/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Polynucleotides encoding mammalian ECM signalling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signalling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signalling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signalling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signalling molecules. Further provided are methods for using mammalian ECM signalling molecules to screen for, and/or modulate, disorders associated with angiogenesis, chondrogenesis, and oncogenesis: ex vivo methods for using mammalian ECM signalling molecules to prepare blood products are also provided.

Claims

exact text as granted — not AI-modified
1 - 64 . (canceled)  
     
     
         65 . A humanized monoclonal antibody that binds specifically to native human Cyr61.

Join the waitlist — get patent alerts

Track US2006257965A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.